[
    {
        "pregunta": "1. What are the first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline?",
        "respuesta": "The first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline are oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular). The choice among these should be made based on patient factors and preferences.",
        "contexto": [
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given similar efficacy and a lower risk of adverse effects, low-dose colchicine over high-dose colchicine is strongly recommended when colchicine is the chosen agent. † There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the",
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>"
        ]
    },
    {
        "pregunta": "2. How is the choice between colchicine, NSAIDs, and glucocorticoids determined in the management of gout flares?",
        "respuesta": "The choice between colchicine, NSAIDs, and glucocorticoids in the management of gout flares, according to the 2020 American College of Rheumatology Guideline, should be made based on patient factors and preferences. This includes considerations such as the patient's comorbidities, medication tolerability, past experiences, and access to the medications. The guideline emphasizes shared decision-making tailored to individual patient circumstances.",
        "contexto": [
            "and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given similar efficacy and a lower risk of adverse effects, low-dose colchicine over high-dose colchicine is strongly recommended when colchicine is the chosen agent. † There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the",
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability of these agents in flare management, particularly when administered early after symptom onset. Appropriate dosing and duration should be guided by the severity of the flare. For colchicine specifically, the FDA-approved dosing should be followed (1.2 mg immediately followed by 0.6 mg an hour later, with ongoing antiinflammatory therapy until the flare resolves). Based on similar efficacy between agents demonstrated in the NMA , the Voting Panel did not further prioritize between the first-line agents, noting that treatment selection should be driven by patient factors (e.g., comorbidity, access, past experience) as part of shared decisionmaking. Likewise, parenteral glucocorticoids were favored over alternative agents when oral dosing is not possible. In patients experiencing an inadequate response to an initial agent, the Voting Panel cited"
        ]
    },
    {
        "pregunta": "3. What is the recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients experiencing a gout flare for whom other anti-inflammatory therapies (such as colchicine, NSAIDs, or glucocorticoids) are poorly tolerated or contraindicated, the guideline conditionally recommends using IL-1 inhibitors over no therapy (beyond supportive/analgesic treatment). This recommendation is based on moderate certainty of the evidence.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>",
            "and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given similar efficacy and a lower risk of adverse effects, low-dose colchicine over high-dose colchicine is strongly recommended when colchicine is the chosen agent. † There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the"
        ]
    },
    {
        "pregunta": "4. What is the preferred adjuvant treatment for gout flares, according to the guideline?",
        "respuesta": "The 2020 American College of Rheumatology Guideline conditionally recommends using topical ice as an adjuvant treatment for patients experiencing a gout flare over no adjuvant treatment. This recommendation is based on low certainty of the evidence.",
        "contexto": [
            "|For patients experiencing a gout flare, we conditionally recommend using topical ice as an adjuvant treatment over no adjuvant treatment.|31|Low|</p>",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare, we conditionally recommend using topical ice as an adjuvant treatment over no adjuvant treatment. Low * PICO = population, intervention, comparator, outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IL-1 = interleukin-1; ACTH = adrenocorticotropic hormone; NPO = nothing by mouth (nulla per os). † High quality of evidence from network meta-analyses supporting canakinumab, which has superior mean pain score reduction and mean day-2 joint tenderness reduction. However, the Voting Panel raised concern that the comparator was weak (triamcinolone 40 mg) and that cost issues significantly favor other agents. Adding vitamin C supplementation is conditionally recommended against for patients with gout, regardless of disease activity. The Voting Panel discussed data demonstrating the important genetic contributions to the development and severity of"
        ]
    },
    {
        "pregunta": "5. What lifestyle factors are conditionally recommended to be limited in patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, the lifestyle factors that are conditionally recommended to be limited in patients with gout include:\n\n1. Alcohol intake\n2. Purine intake\n3. High-fructose corn syrup\n\nThese recommendations apply regardless of the disease activity and are based on low to very low certainty of evidence.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "2020 American College of Rheumatology Guideline for the Management of Gout  FACP  American College of Rheumatology      F80A3E8AB0860BDC6587873AB54E2F45 10.1002/acr.24180 received research support from Hikma Pharmaceuticals and Horizon Pharma. Dr. Singh has received consulting fees, speaking fees, and/or honoraria from Crealta/ Horizon, Medisys, Fidia, UBM, Trio Health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, and Practice Point Communications Submitted for publication December 10, 2019; accepted in revised form February 28, 2020.  INTRODUCTION Gout is the most common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the US METHODS This guideline follows the ACR guideline development process ( https://www.rheum atolo gy.org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines https://www.rheum atolo gy. org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines/ Gout",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT in individuals with asymptomatic hyperuricemia, which is defined as an SU concentration of ≥6.8 mg/dl with no prior gout flares or subcutaneous tophi. Patients with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi. These guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension,",
            "medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that inform a research agenda for gout management. While data support an active treat-to-target strategy, a question remains as to what may be the optimal SU threshold for patients with more severe disease, in addition to questions about threshold values in specific populations of gout patients. Gout has differential impact on patients by sex, race, or by presence of other comorbidities. This guideline is limited in commenting on specific groups of gout patients, as more studies of specific patient cohorts are needed in order to"
        ]
    },
    {
        "pregunta": "6. What is the recommendation regarding the use of vitamin C supplementation in patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients with gout, regardless of disease activity, it is conditionally recommended against adding vitamin C supplementation. This recommendation is based on low certainty of evidence.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT in individuals with asymptomatic hyperuricemia, which is defined as an SU concentration of ≥6.8 mg/dl with no prior gout flares or subcutaneous tophi. Patients with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi. These guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension,",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "This guideline is limited in commenting on specific groups of gout patients, as more studies of specific patient cohorts are needed in order to make differential recommendations. Additional studies are needed to determine the safety of prolonged and profound treatmentrelated hypouricemia (e.g., SU ≤3 mg/dl), an important knowledge gap given that epidemiologic studies have suggested an inverse association of SU concentration with select neurodegenerative disorders Gout has been characterized as a \"curable disease\" Based on recent nurse-    Supported by the American College of Rheumatology",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|"
        ]
    },
    {
        "pregunta": "7. When should hydrochlorothiazide be switched to an alternate antihypertensive in patients with gout?",
        "respuesta": "In patients with gout, regardless of disease activity, switching hydrochlorothiazide to an alternate antihypertensive is conditionally recommended when feasible. This recommendation is based on very low certainty of evidence.",
        "contexto": [
            "by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose",
            "<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>\n\n<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|\n|We conditionally recommend against stopping low-dose aspirin (in those who are taking this medication for appropriate indications).|47|Very low|\n|We conditionally recommend against adding or switching to fenofibrate.|47|Very low|</p>\n\n<h2>* PICO = population, intervention, comparator, outcomes.</h2>",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the recommendation against initiating ULT in this patient group. Initiating ULT is conditionally recommended against in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, RCTs (designed to study CVD outcomes) demonstrated significant reduction in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2",
            "NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific antiinflammatory prophylaxis should be based upon patient factors. Moderate We strongly recommend continuing prophylaxis for 3-6 months rather than <3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares. Moderate When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved. Moderate We strongly recommend against pegloticase as first-line therapy. 10 Moderate † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; NSAIDs = nonsteroidal antiinflammatory drugs. † Moderate evidence is in support of the efficacy of pegloticase, but due to cost, safety concerns, and favorable benefit-to-harm ratios of other untried treatment options, the recommendation is"
        ]
    },
    {
        "pregunta": "8. What is the recommended antihypertensive agent of choice for patients with gout?",
        "respuesta": "The 2020 American College of Rheumatology Guideline conditionally recommends choosing losartan preferentially as an antihypertensive agent for patients with gout when feasible.",
        "contexto": [
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose",
            "2020 American College of Rheumatology Guideline for the Management of Gout  FACP  American College of Rheumatology      F80A3E8AB0860BDC6587873AB54E2F45 10.1002/acr.24180 received research support from Hikma Pharmaceuticals and Horizon Pharma. Dr. Singh has received consulting fees, speaking fees, and/or honoraria from Crealta/ Horizon, Medisys, Fidia, UBM, Trio Health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, and Practice Point Communications Submitted for publication December 10, 2019; accepted in revised form February 28, 2020.  INTRODUCTION Gout is the most common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the US METHODS This guideline follows the ACR guideline development process ( https://www.rheum atolo gy.org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines https://www.rheum atolo gy. org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines/ Gout",
            "ULT initiation In contrast to the 2012 ACR Guidelines for the Management of Gout (which did not consider treatment costs), this document firmly places allopurinol as the preferred first-line ULT for all patients, including those with CKD, due to the respective cost of each medication and potential CVD safety concerns that have recently emerged with febuxostat Under GRADE methodology, recommendations in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications?",
        "respuesta": "The information regarding the recommendation for the use of low-dose aspirin in patients with gout who are taking it for appropriate indications is not available in the provided content from the 2020 American College of Rheumatology Guideline.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT in individuals with asymptomatic hyperuricemia, which is defined as an SU concentration of ≥6.8 mg/dl with no prior gout flares or subcutaneous tophi. Patients with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi. These guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension,",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to"
        ]
    },
    {
        "pregunta": "10. What are the indications for initiating pharmacologic urate-lowering therapy (ULT) in patients with gout according to the guideline?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, initiating pharmacologic urate-lowering therapy (ULT) is strongly recommended for gout patients with any of the following:\n\n1. ≥1 subcutaneous tophi.\n2. Evidence of radiographic damage (any modality) attributable to gout.\n\nThe guidelines indicate these as clear indications for starting ULT.",
        "contexto": [
            "<h1>Table 1. Indications for pharmacologic urate-lowering therapy (ULT)*</h1>",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "ULT initiation In contrast to the 2012 ACR Guidelines for the Management of Gout (which did not consider treatment costs), this document firmly places allopurinol as the preferred first-line ULT for all patients, including those with CKD, due to the respective cost of each medication and potential CVD safety concerns that have recently emerged with febuxostat Under GRADE methodology, recommendations in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without",
            "medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that inform a research agenda for gout management. While data support an active treat-to-target strategy, a question remains as to what may be the optimal SU threshold for patients with more severe disease, in addition to questions about threshold values in specific populations of gout patients. Gout has differential impact on patients by sex, race, or by presence of other comorbidities. This guideline is limited in commenting on specific groups of gout patients, as more studies of specific patient cohorts are needed in order to",
            "who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the recommendation against initiating ULT in this patient group. Initiating ULT is conditionally recommended against in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, RCTs (designed to study CVD outcomes) demonstrated significant reduction in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2"
        ]
    }
]